Sign In
Buy IMCR
$29.20
-0.150 (-0.511%)
At Close: Jun 23, 2026
Immunocore reports third quarter financial results and provides a business update
07:00am, Wednesday, 06'th Nov 2024
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cut
Immunocore (IMCR) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 05'th Nov 2024
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
03:00am, Saturday, 14'th Sep 2024
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore to present at the 2024 Cantor Global Healthcare Conference
04:05pm, Thursday, 12'th Sep 2024
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
11:40am, Friday, 30'th Aug 2024
In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melano
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
04:12am, Monday, 12'th Aug 2024
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C f
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
06:53am, Sunday, 11'th Aug 2024
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato
3 Small-Cap Stocks with Significant Growth Potential
10:41am, Tuesday, 06'th Aug 2024
The Federal Reserve seems prepared to cut interest rates, perhaps by its next meeting in September. That's one reason that institutional dollars are starting to rotate into small-cap growth stocks.
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Immunocore to present at the Jefferies Global Healthcare Conference
04:00pm, Thursday, 30'th May 2024
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
12:00pm, Friday, 24'th May 2024
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Immunocore reports first quarter financial results and provides a business update
07:00am, Wednesday, 08'th May 2024
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 add
Immunocore announces upcoming presentation and posters at ASCO 2024
10:00am, Wednesday, 24'th Apr 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presen
